Telomir Pharmaceuticals Reports Telomir-1 Outperforms Rapamycin and Chemo in Prostate Cancer Model

Reuters10-23

<a href="https://laohu8.com/S/TELO">Telomir Pharmaceuticals</a> Reports Telomir-1 Outperforms Rapamycin and Chemo in Prostate Cancer Model

Telomir Pharmaceuticals Inc. has announced new preclinical data from a study evaluating its investigational compound, Telomir-1, in an aggressive prostate cancer model. The results, which have already been reported by the company, indicate that Telomir-1 reduces DNA methylation of the CASP8 and GSTP1 genes-both of which regulate key cell death and detoxification pathways often disrupted in cancer. Compared to chemotherapy and the mTOR pathway inhibitor Rapamycin, Telomir-1 demonstrated a more sustained reduction in DNA methylation over a 21-day period. The company noted that combined therapy with Telomir-1 and chemotherapy showed lower methylation levels than chemotherapy alone, suggesting potential for enhanced epigenetic effects. These findings may inform ongoing research on Telomir-1 in oncology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018907), on October 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2577131542?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-23 04:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577131542","market":"us","top_or_hot":-1,"title":"Telomir Pharmaceuticals Reports Telomir-1 Outperforms Rapamycin and Chemo in Prostate Cancer Model","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TELO\">Telomir Pharmaceuticals</a> Reports Telomir-1 Outperforms Rapamycin and Chemo in Prostate Cancer Model\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Telomir Pharmaceuticals Inc. has announced new preclinical data from a study evaluating its investigational compound, Telomir-1, in an aggressive prostate cancer model. The results, which have already been reported by the company, indicate that Telomir-1 reduces DNA methylation of the CASP8 and GSTP1 genes-both of which regulate key cell death and detoxification pathways often disrupted in cancer. Compared to chemotherapy and the mTOR pathway inhibitor Rapamycin, Telomir-1 demonstrated a more sustained reduction in DNA methylation over a 21-day period. The company noted that combined therapy with Telomir-1 and chemotherapy showed lower methylation levels than chemotherapy alone, suggesting potential for enhanced epigenetic effects. These findings may inform ongoing research on Telomir-1 in oncology.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018907), on October 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telomir Pharmaceuticals Reports Telomir-1 Outperforms Rapamycin and Chemo in Prostate Cancer Model</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelomir Pharmaceuticals Reports Telomir-1 Outperforms Rapamycin and Chemo in Prostate Cancer Model\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-23 04:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TELO\">Telomir Pharmaceuticals</a> Reports Telomir-1 Outperforms Rapamycin and Chemo in Prostate Cancer Model\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Telomir Pharmaceuticals Inc. has announced new preclinical data from a study evaluating its investigational compound, Telomir-1, in an aggressive prostate cancer model. The results, which have already been reported by the company, indicate that Telomir-1 reduces DNA methylation of the CASP8 and GSTP1 genes-both of which regulate key cell death and detoxification pathways often disrupted in cancer. Compared to chemotherapy and the mTOR pathway inhibitor Rapamycin, Telomir-1 demonstrated a more sustained reduction in DNA methylation over a 21-day period. The company noted that combined therapy with Telomir-1 and chemotherapy showed lower methylation levels than chemotherapy alone, suggesting potential for enhanced epigenetic effects. These findings may inform ongoing research on Telomir-1 in oncology.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018907), on October 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL3qRFY:1","article_id":"2577131542","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577131542","pubTimestamp":1761163357,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Telomir Pharmaceuticals Inc. has announced new preclinical data from a study evaluating its investigational compound, Telomir-1, in an aggressive prostate cancer model. The results, which have already been reported by the company, indicate that Telomir-1 reduces DNA methylation of the CASP8 and GSTP1 genes-both of which regulate key cell death and detoxification pathways often disrupted in cancer. Compared to chemotherapy and the mTOR pathway inhibitor Rapamycin, Telomir-1 demonstrated a more sustained reduction in DNA methylation over a 21-day period. The company noted that combined therapy with Telomir-1 and chemotherapy showed lower methylation levels than chemotherapy alone, suggesting potential for enhanced epigenetic effects. These findings may inform ongoing research on Telomir-1 in oncology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated con","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TELO":"Telomir Pharmaceuticals"},"translate_title":"Telomir Pharmaceuticals报告Telomir-1在前列腺癌模型中的表现优于雷帕霉素和化疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TELO":0.9},"content_text":"Telomir Pharmaceuticals Reports Telomir-1 Outperforms Rapamycin and Chemo in Prostate Cancer Model\n    \n\n        Telomir Pharmaceuticals Inc. has announced new preclinical data from a study evaluating its investigational compound, Telomir-1, in an aggressive prostate cancer model. The results, which have already been reported by the company, indicate that Telomir-1 reduces DNA methylation of the CASP8 and GSTP1 genes-both of which regulate key cell death and detoxification pathways often disrupted in cancer. Compared to chemotherapy and the mTOR pathway inhibitor Rapamycin, Telomir-1 demonstrated a more sustained reduction in DNA methylation over a 21-day period. The company noted that combined therapy with Telomir-1 and chemotherapy showed lower methylation levels than chemotherapy alone, suggesting potential for enhanced epigenetic effects. These findings may inform ongoing research on Telomir-1 in oncology.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018907), on October 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577131542","isCrawlerRequest":true}